Mayne Pharma
The register now connects TWYNEO with the existing RHOFADE and EPSOLAY reviews. Their acne and rosacea records address different conditions and should be read with each product's own label and review date.
MODEL
Named distributor in the current TWYNEO manufacturer label; medicine obtained through a prescription and pharmacy.
The brand verdict
The current manufacturer information identifies Mayne Pharma and a 30 g TWYNEO pump. Older Galderma documents remain discoverable, making the version of the source relevant to pack and handling information.
The reviewed TWYNEO label contains an unresolved inconsistency in one efficacy-table row. The product review records it rather than silently repairing a number or using it to claim superiority.
RHOFADE and EPSOLAY remain separate rosacea records in the register. Adding an acne product does not make their indications or study outcomes directly comparable. Read each assessment at its own review date.
- Provides a full prescribing-information document.
- The label specifies formulation and handling details.
The range
- R-522026-08-02
Epsolay
MICROENCAPSULATED BENZOYL PEROXIDE CREAM 5%Benzoyl peroxide is the last thing you would put on rosacea skin. Sealed inside silica microcapsules that release it slowly, it produced 47.4% and 49.2% treatment success with application-site pain in 2% of users. This is the best formulation engineering in the register.
RECOMMENDED$563 PER 30 G AIRLESS PUMP
- R-752026-09-13
TWYNEO Cream
An approved acne cream that shows why compatibility depends on the finished product. The current label also makes storage dates unusually important and contains a trial-table discrepancy worth preserving in the record.
CONDITIONALPharmacy quote PER DISPENSED PUMP
- R-412026-08-02
Rhofade
OXYMETAZOLINE HYDROCHLORIDE CREAM 1%A vasoconstrictor for the redness of rosacea, and the only product in this register whose own registration trials show fewer than one user in five reaching the endpoint. It does not treat the disease. It constricts the vessels for part of a day, every day, for as long as you keep applying it.
CAUTION$150 PER TUBE
What repeats across the range
These findings are drawn from the reviewed offerings above. They describe the assessed range, rather than every product or service the company provides.
- 01
Version the label, not just the brand name
Use the instructions supplied with the actual dispensed product. A historical approval document can establish an earlier record while giving a pack size or opening limit that differs from today's manufacturer information.
- 02
Keep one product's scope visible
A disclosed formula and controlled trial do not provide an assessment of every medicine in a corporate catalogue. This profile connects the three reviewed records without treating them as a portfolio-wide audit.
Disclosure scorecard
Not what is in the product — what the company publishes about it, and where. “Findable” means the concentration exists somewhere, such as a help-centre article, rather than on the page you buy from.
SCROLL THE TABLE SIDEWAYS
| PRODUCT | OFFICIAL SOURCE | PERSONAL OUTCOMES TESTED |
|---|---|---|
| TWYNEO Cream | YES | NO |
| Rhofade | YES | NO |
| Epsolay | YES | NO |
Reviewed options
Sources
- S-01TWYNEO — current manufacturer prescribing information
February 2025 label names Mayne Pharma and a 30 g pump. Trial 1 success and difference figures in Table 4 conflict; that row is not charted here. Storage limits are product-specific. Checked 13 September 2026.
- S-02FDA — original TWYNEO approval label
Historical 2021 label used only to investigate the Trial 1 table discrepancy. Its older pack size and opening limit are not used for current purchasing advice. Checked 13 September 2026.